QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
Venlo, the Netherlands, and Redwood City, California, May 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services (SaaS) solution …